A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non–small cell lung cancer …
S Alfonso, A Valdés-Zayas, ER Santiesteban… - Clinical Cancer …, 2014 - AACR
Purpose: Racotumomab-alum is an anti-idiotype vaccine targeting the NeuGcGM3 tumor-
associated ganglioside. This clinical trial was conducted to provide a preliminary estimate of …
associated ganglioside. This clinical trial was conducted to provide a preliminary estimate of …
Racotumomab: an anti-idiotype vaccine related to N-glycolyl-containing gangliosides – preclinical and clinical data
AM Vázquez, AM Hernández, A Macías… - Frontiers in …, 2012 - frontiersin.org
Neu-glycolyl (NeuGc)-containing gangliosides are attractive targets for immunotherapy with
anti-idiotype mAbs, because these glycolipids are not normal components of the cytoplasmic …
anti-idiotype mAbs, because these glycolipids are not normal components of the cytoplasmic …
[PDF][PDF] Racotumomab-a novel anti-idiotype monoclonal antibody vaccine for the treatment of cancer
Z Gajdosik - Drugs Today (Barc), 2014 - scholar.archive.org
Racotumomab is a murine gamma-type anti-idiotype monoclonal antibody that specifically
induces an antibody response against Neu-glycolyl GM3 ganglioside (NeuGcGM3), which is …
induces an antibody response against Neu-glycolyl GM3 ganglioside (NeuGcGM3), which is …
[HTML][HTML] Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung …
B Besse, E Felip, RG Campelo, M Cobo, C Mascaux… - Annals of …, 2023 - Elsevier
Background Patients with advanced non-small-cell lung cancer (NSCLC) treated with
immune checkpoint blockers (ICBs) ultimately progress either rapidly (primary resistance) or …
immune checkpoint blockers (ICBs) ultimately progress either rapidly (primary resistance) or …
A phase III clinical trial of the epidermal growth factor vaccine CIMAvax-EGF as switch maintenance therapy in advanced non–small cell lung cancer patients
PC Rodriguez, X Popa, O Martínez, S Mendoza… - Clinical Cancer …, 2016 - AACR
Purpose: EGFR is a well-validated target for patients with non–small cell lung cancer
(NSCLC). CIMAvax-EGF is a therapeutic cancer vaccine composed of human recombinant …
(NSCLC). CIMAvax-EGF is a therapeutic cancer vaccine composed of human recombinant …
Immunotherapeutic agents in non-small-cell lung cancer finally coming to the front lines
Non-small-cell lung cancer usually carries a dismal prognosis. Novel treatment approaches
are clearly warranted. Immunotherapy has emerged as a promising area of research …
are clearly warranted. Immunotherapy has emerged as a promising area of research …
CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine
M Tagliamento, E Rijavec, G Barletta… - Expert Opinion on …, 2018 - Taylor & Francis
Introduction: Lung cancer represents the most common cause of cancer death worldwide.
While the prognosis remains poor, immunotherapy is giving a positive impact on survival …
While the prognosis remains poor, immunotherapy is giving a positive impact on survival …
Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial
E Quoix, R Ramlau, V Westeel, Z Papai… - The lancet …, 2011 - thelancet.com
Background Chemotherapy is the standard of care for advanced stages of non-small-cell
lung cancer (NSCLC). TG4010 is a targeted immunotherapy based on a poxvirus (modified …
lung cancer (NSCLC). TG4010 is a targeted immunotherapy based on a poxvirus (modified …
[HTML][HTML] Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development
L Decoster, I Wauters, JF Vansteenkiste - Annals of oncology, 2012 - Elsevier
The historical results of cancer vaccination for non-small-cell lung cancer (NSCLC) were
disappointing. In the current decade, however, new insights in the interaction between …
disappointing. In the current decade, however, new insights in the interaction between …
Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC
C Zhou, Z Wang, M Sun, L Cao, Z Ma, R Wu, Y Yu… - Nature cancer, 2023 - nature.com
The randomized, double-blinded, multi-center, phase III GEMSTONE-302 (NCT03789604)
study evaluated the efficacy and safety of sugemalimab versus placebo in combination with …
study evaluated the efficacy and safety of sugemalimab versus placebo in combination with …